{"id":"W4229070154","doi":"10.1016/j.annonc.2022.03.280","title":"LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Population; Breast cancer; Hazard ratio; Cancer; Randomized controlled trial; Adjuvant; Oncology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003040822,0.001006549,0.001877614,0.000603596,0.000287341,0.001486508,0.001071418,0.0007606279,0.005031063],"category_scores_gemma":[0.002139947,0.0003155723,0.002313715,0.0006661076,0.0003431657,0.001043014,0.0008322817,0.001840914,0.00100275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00106803,"about_ca_system_score_gemma":0.0009265261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001637424,"about_ca_topic_score_gemma":0.004679066,"domain_scores_codex":[0.9991447,0.0004533664,0.00003802661,0.0001315223,0.00009693566,0.0001354384],"domain_scores_gemma":[0.9989981,0.0002327849,0.0003208151,0.0001206222,0.00009177134,0.0002358858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6154625,0.002244901,0.09437688,0.002164983,0.01570421,0.0003245547,0.0001864234,0.01289825,0.01159643,0.0007115905,0.05224588,0.1920833],"study_design_scores_gemma":[0.2814295,0.096103,0.4982236,0.0006539541,0.03380978,0.001394027,0.0003408753,0.01513097,0.006062839,0.003641829,0.06293734,0.0002724281],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.924179,0.01689654,0.001216307,0.002089771,0.0003156232,0.0004713185,0.04544737,0.0004295647,0.008954477],"genre_scores_gemma":[0.9159907,0.003376007,0.001267471,0.001662171,0.0003742725,0.0008484392,0.06976928,0.0001342982,0.006577391],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005031063,"threshold_uncertainty_score":0.01683056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03958723953281931,"score_gpt":0.3508341019965855,"score_spread":0.3112468624637663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}